BGB-B2033

Phase 1Small molecule

BGB-B2033 is one of 5 small molecule programs targeting Metastatic Hepatocellular Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Hepatocellular CarcinomaRecruiting

Metastatic Hepatocellular CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Metastatic Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

1 2

Lenvima

Eisai

Phase 2

1 3

Beyfortus

BeiGene

Phase 1

1 4

Avastin

BBio-Thera Solutions

Phase 1

1 5

BGB-B2033

BBeOne Medicines

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Metastatic Hepatocellular Carcinoma

NCT06427941

Clinical

Trials by Indication[1]

Metastatic Hepatocellular Carcinoma1 trial

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

Recruiting·BBeOne Medicines·Phase 1·NCT06427941·392 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BGB-B2033. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGB-B2033 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGB-B2033. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeOne Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBeOne Medicines

BGB-B2033

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Metastatic Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News